R&D News | pharmaphorum

News

Sanofi/GSK restart COVID-19 vaccine trials after tweaking fo...

Sanofi and GlaxoSmithKline are restarting clinical development of their COVID-19 vaccine, which was delayed after hitting a snag late last year.

News

Lilly cuts a $960m deal with Rigel on RIP kinase

Eli Lilly has become the latest drugmaker to have a go at developing RIP kinase inhibitors, a new class of drugs with potential in autoimmune and inflammatory disease, paying $125 million u

News

Could CRISPR cure HIV? US biotech Excision raises $60m to fi...

US biotech Excision BioTherapeutics has raised $60 million to test a potential HIV cure in the clinic, which would use CRISPR technology to snip out the viral code from human cells and tiss

News

A New Era of Collaboration and Innovation

South African variant may cut response from Pfizer/BioNTech ...

The South African coronavirus variant may cut the effectiveness of Pfizer/BioNTech’s vaccine by around two thirds, according to a laboratory study.

News

GSK expands coronavirus antibody tie-up to include potential...

GlaxoSmithKline is expanding a coronavirus antibody collaboration with US biotech Vir, to include potential therapies for flu and other respiratory viruses.

News

Life science leaders sign new ‘Biotech Social Pact’ for Europe

Mega biotech Centessa beams up ex-Warp Speed science chief S...

Operation Warp Speed's former science chief Moncef Slaoui is to lead research at a new mega-biotech called Centessa, formed by the merger of 10 privately-held life science startups.

Sanofi/GSK restart COVID-19 vaccine trials after tweaking fo...

Lilly cuts a $960m deal with Rigel on RIP kinase

Could CRISPR cure HIV? US biotech Excision raises $60m to fi...

South African variant may cut response from Pfizer/BioNTech ...

GSK expands coronavirus antibody tie-up to include potential...

Mega biotech Centessa beams up ex-Warp Speed science chief S...

UCB buys cell therapy biotech Candid for $2bn upfront

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks